Upsher-Smith launches 3 generics

Upsher-Smith is bringing three generics to market. The Maple Grove, Minn.-based company is launching its generics of Luvox (fluvoxamine maleate tablets), haloperidol tablets and clonidine hydrochloride extended-release tablets.

The company's Luvox generic is indicated to treat patients with obsessive-compulsive disorder. The haloperidol tablets are indicated in the management of psychotic disorders, as well as the control of tics and vocal utterances of Tourette's disorder in children and adults. Upsher-Smith's generic Kapvay is indicated as a treatment for attention deficit-hyperactivity disorder.

The three products have a combined market value of nearly $102.5 million for the 12 months ended December 2019, according to IQVIA.

“We enter this new decade not only with our most aggressive growth plan in history, but also prepared to meet the challenging market conditions that lie ahead,” said Rusty Field, Upsher-Smith president and CEO. “We’re proud of our strong reputation as a trusted partner in the generic marketplace and look forward to delivering even more affordable options to patients and healthcare professionals.”